common.study.topics.clinical

Assessment of DHA on Reducing Early Preterm Birth

common.study.values.description

Assessment of DHA On Reducing Early Preterm Birth

The purpose of this study is to determine if giving a larger amount of DHA than currently included in some prenatal supplements can reduce early preterm birth (birth before 34 weeks of pregnancy).

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Docosahexaenoic acid - 800mg/day

All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)

Drug - Docosahexaenoic acid - 200mg/day

The control group will receive 1-capsule containing 200 mg DHA/d.

Placebo

Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Assessment of DHA On Reducing Early Preterm Birth (ADORE Trial)

common.study.values.clinical-trial-id

NCT02626299

participant.views.study.view.id

mepBmb